Background: Production of lower concentrations of prolactin in fetus is considered as one of the major contributor for the development of respiratory distress syndrome (RDS) in newborns considerably in pregnants with maternal complications. Hence the present study was conducted with the objective to measure the serum level of cord blood prolactin in normal pregnancy and in pregnancy with maternal complications and its association with development of RDS in newborn.Methods: In this prospective study of 100 women, 28 with normal pregnancy (Group A) and 72 with abnormal pregnancies (Group B) were included in the study. Umbilical cord blood was collected and serum prolactin level was estimated using radio-immuno assay. The obtained values were correlated with prevalence of RDS in neonates and maternal complications.Results: The average age of pregnant women participated in Group A was 26 years and Group B was 27 years. In Group A 2 babies with birth weight of 2001-3000 gm had a cord serum prolactin level of 216±137.8 ng/mL developed RDS. In Group B the level of prolactin was 285±276 and 326±132 ng/mL in 4 RDS babies with birth weight of <1000 gm and 1000-2000 gm respectively. It was observed that cord serum prolactin levels had no correlation with the mode of delivery, sex of newborn, steroid therapy. In Group A, 2 neonates developed RDS which were of gestational age between 32-35 weeks with mean prolactin level of 216 ng/ml, while in Group B, 1 neonate with gestational age less than 32 weeks and mean prolactin level of 480 and 4 neonates of 32-35 weeks with mean prolactin level of 266 ng/mL developed RDS. Out of 27 mothers with complications of PIH, 3 developed RDS. 1 case each from IUGR and twins developed RDS respectively.Conclusions: The risk of RDS is less in newborn with high prolactin level than in newborns with low prolactin levels. So prolactin might have a role in fetal lung maturation.
Recurrent implantation failure is most distressing condition to both couple as well as doctor in the field of reproductive medicine. Patients have already undergone various ART treatments with no favourable outcome and are drained emotionally as well as economically. To overcome this obstacle a comprehensive approach is needed. In this case report, we are addressing a couple who came to us with primary infertility of 15 yrs, with recurrent IVF failures (four cycles of IUI, seven cycles of ICSI both fresh and frozen and with ovum donation in last two cycle), with poor ovarian reserve and male factor infertility for surrogacy as a last option. After complete evaluation of couple, recurrent Implantation failure is thought to be due to poor endometrium and bad embryo quality, and we counselled couple to go for ovum donation and ICSI before considering surrogacy. To improve endometrial receptivity we performed local endometrial injury, oral estradiol therapy, intrauterine G-CSF instillation and IVIG etc. Simultaneously for better quality of embryo we decided to choose ovum donation due to poor ovarian reserve and advance age of the patient and ICSI was done with husband sperm after treatment of male factor infertility and ET was performed. Patient conceived in first cycle with single live intrauterine pregnancy, her antenatal course was uneventful and delivered a healthy baby at term without any complication.
INTRODUCTIONInfertility is defined as failure of a couple to achieve spontaneous pregnancy even after regular unprotected sexual intercourse in one year.1 Affects about 15% of couples.2 Both male and female contributes to infertility. Male factor is responsible for 30% of cases and contributes to an additional 20% in combination with female factor. Thus 50% of cases of infertility can be explained by combined male and female factors. 2,3 When the cause of infertility cannot be identified, the condition is termed idiopathic. It is seen in 25% of men. 2Men with idiopathic infertility present with no significant history and have normal physical examination and hormonal profile. However, semen analysis reveals a decreased sperm concentration, decreased sperm motility, and increase abnormal forms of sperm. These sperm abnormalities when occur together are called oligoastheno-teratozoospermia (OAT) syndrome. ABSTRACTBackground: Male contributes about 50% for cases with combined male and female infertility. When the cause is not known, it is term as idiopathic infertility. It affects 25% of men. Many advances have been made in reproductive medicine which provides great opportunities, couples which were considered untreatable now have got chance to have their own babies. Various ART procedures like ICSI have been proven as an efficient therapy in severe male factor infertility. However, the cost per cycle and complications such as multiple gestations cannot be ignored. Medical management of infertility can be specific or empirical depending on etiology. Specific medical management is use when certain etiology is identified. However, in absence of specific etiology use of empirical medical treatment can be attempted in order to improve treatment results. In this study our aim is to evaluate the effect of human chorionic gonadotropin (hCG) and antioxidants on semen parameters in men with idiopathic male infertility. Methods: Thirty men with abnormal semen parameters were included in study. Patients were treated with injection hCG-2000 IU three times a week for three months along with the antioxidants. After 3 months of treatment repeat semen analysis were performed and results were compared with pre-treated seminal parameters. Results: Results showed significant increase in sperm count (p value ≤ 0.001), total motility (p value=<0.001), and progressive forward motility (p value = <0.001), while no significant difference is seen in rest of the parameters. Conclusions: Use of hCG and antioxidants in idiopathic male infertility can significantly improve seminal parameters in idiopathic male infertility.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.